The company has received the US Food and Drug Administration (FDA) clearence for Prontosan Wound Management Gel for OTC use in November 2010.
B Braun Medical said the product is used for cleaning, moisturising and decontamination of acute and chronic wounds, to aid in efficient wound bed preparation.
The Prontosan Wound Management gel contains PHMB and Betaine, the surfactant for the cleansing and moistening of wounds.
B Braun Medical Infection Control Products Marketing director Mike Kelly said the 510(k) clearance for over-the-counter use of Prontosan Wound Management gel advances B Braun’s commitment to infection prevention, helping to provide solutions that positively impact patients’ care – in a physician’s office, acute care setting or in a patient’s home.